Show Notes
Welcome to the first episode of The Threshold, a Foreign Policy podcast about the fight to end infectious diseases around the world and the innovations that could get us there. Host Henry Bonsu speaks with Gates CEO Mark Suzman and WACI Health Executive Director Rosemary Mburu about why they’re both optimistic and concerned about the future of disease elimination. And there is a big deadline on their minds that directly impacts the state of global health—which is in a tough place.
More than two million people die every year from the world’s biggest infectious diseases: HIV/AIDS, malaria, and tuberculosis. TB alone claimed more than 1.25 million lives in 2023, overtaking COVID as the world’s deadliest infectious disease.
On the surface, the fight to end these epidemics is harder now than it’s ever been. Aid for global health dropped more than 20 percent this year, driven in large part by cuts to USAID and British government programs.
But for the first time in decades, science is much closer to ending these diseases. Recent advances—including an HIV prevention shot, TB vaccine candidates, and innovative tools to end malaria—could significantly reduce their prevalence.
Over the next seven episodes, we’ll explore how new scientific breakthroughs are making a huge difference in the fight against epidemics like HIV/AIDS, tuberculosis, and malaria. But also, we’ll tackle how we can approach global health funding at this geopolitically fraught moment.
At a live panel discussion recorded at Foreign Policy’s Health Forum, Suzman and Mburu explain why they believe we could eliminate HIV, TB, and malaria within our lifetimes. Plus, they discuss why they think the Global Fund’s replenishment round in November is critical. The Threshold is made possible in part through funding from the Gates Foundation. (Photo credit: Jonathan Heisler)
Guests and organizations:
Gates CEO Mark Suzman
WACI Health Executive Director Rosemary Mburu
More from The Threshold
We hosted a live virtual podcast taping of The Threshold on World Neglected Tropical Disease Day. Host Henry Bonsu spoke with Sabena Solomon, GSK vice president and head of global health access, and Sam Macintosh, the END Fund’s vice president of global strategic partnerships, about pharmaceutical companies’ unique role in the fight to end NTDs. Since 2000, dozens of countries have eliminated at least one NTD. This is in part thanks to pharmaceutical industry partners, who have donated over 30 billion tablets and vials toward ending NTDs. During this special event, which was made possible through funding from the Gates Foundation, we explored what is needed in this current moment to keep the momentum towards ending neglected tropical diseases.
In our season finale of The Threshold, we delve into what it will take to end neglected tropical diseases (NTDs), which impact about 1.5 billion people. The World Health Organization considers 21 diseases to be NTDs, a classification that marks a disease as underfunded and prioritized relative to its burden. What is encouraging is that a growing number of neglected tropical diseases are closer than ever to being eliminated.
What are the best ways to stop the spread of infectious diseases? One key element is diagnostics. For diseases like tuberculosis, there are millions of people unaware that they have the disease. So improving diagnostic tests and making them accessible are critical.
Malaria kills nearly six hundred thousand people every year, with 95 percent of deaths occurring in Africa. Most of them are children under five. While progress on curbing malaria has flattened in recent years, new scientific breakthroughs may bring the world closer than ever not only to controlling malaria outbreaks, but potentially also eradicating the disease.
Tuberculosis claimed more than 1.25 million lives in 2023, overtaking COVID as the world’s deadliest infectious disease. For the last century, there has been a vaccine protecting children from TB. Now, there is hope for a new solution: a potential vaccine for adolescents and adults.